Literature DB >> 11592763

A prognostic model for ovarian cancer.

T G Clark1, M E Stewart, D G Altman, H Gabra, J F Smyth.   

Abstract

About 6000 women in the United Kingdom develop ovarian cancer each year and about two-thirds of the women will die from the disease. Establishing the prognosis of a woman with ovarian cancer is an important part of her evaluation and treatment. Prognostic models and indices in ovarian cancer should be developed using large databases and, ideally, with complete information on both prognostic indicators and long-term outcome. We developed a prognostic model using Cox regression and multiple imputation from 1189 primary cases of epithelial ovarian cancer (with median follow-up of 4.6 years). We found that the significant (P< or = 0.05) prognostic factors for overall survival were age at diagnosis, FIGO stage, grade of tumour, histology (mixed mesodermal, clear cell and endometrioid versus serous papillary), the presence or absence of ascites, albumin, alkaline phosphatase, performance status on the ZUBROD-ECOG-WHO scale, and debulking of the tumour. This model is consistent with other models in the ovarian cancer literature; it has better predictive ability and, after simplification and validation, could be used in clinical practice. Copyright 2001 Cancer Research Campaign

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592763      PMCID: PMC2375096          DOI: 10.1054/bjoc.2001.2030

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma.

Authors:  M Brinkhuis; J P Baak; G A Meijer; P J van Diest; O Mogensen; P Bichel; J P Neijt
Journal:  J Clin Pathol       Date:  1996-02       Impact factor: 3.411

Review 2.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

3.  Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients.

Authors:  E J Junor; D J Hole; L McNulty; M Mason; J Young
Journal:  Br J Obstet Gynaecol       Date:  1999-11

4.  Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review.

Authors:  M.S. Carey; A.J. Dembo; J.E. Simm; A.W. Fyles; T. Treger; R.S. Bush
Journal:  Int J Gynecol Cancer       Date:  1993-01       Impact factor: 3.437

5.  Advanced ovarian cancer. Neural network analysis to predict treatment outcome.

Authors:  H J Kappen; J P Neijt
Journal:  Ann Oncol       Date:  1993       Impact factor: 32.976

6.  EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value.

Authors:  H Meden; D Marx; T Raab; M Kron; A Schauer; W Kuhn
Journal:  J Obstet Gynaecol (Tokyo 1995)       Date:  1995-04

7.  Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma.

Authors:  B Lund; P Williamson; H C van Houwelingen; J P Neijt
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

8.  Clinico-pathological correlates in ovarian cancer.

Authors:  A J Dembo; R S Bush; T C Brown
Journal:  Bull Cancer       Date:  1982       Impact factor: 1.276

9.  CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer.

Authors:  C Peters-Engl; A Obermair; H Heinzl; P Buxbaum; P Sevelda; M Medl
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

10.  The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma.

Authors:  S Kehoe; J Powell; S Wilson; C Woodman
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more
  55 in total

1.  A molecularly targeted theranostic probe for ovarian cancer.

Authors:  Wenxue Chen; Rizia Bardhan; Marc Bartels; Carlos Perez-Torres; Robia G Pautler; Naomi J Halas; Amit Joshi
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

2.  Prognostic impact of anatomic resection for hepatocellular carcinoma.

Authors:  Kiyoshi Hasegawa; Norihiro Kokudo; Hiroshi Imamura; Yutaka Matsuyama; Taku Aoki; Masami Minagawa; Keiji Sano; Yasuhiko Sugawara; Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

3.  The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.

Authors:  Guro Aune; Astrid K Stunes; Solveig Tingulstad; Oyvind Salvesen; Unni Syversen; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2011-06-11

4.  Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies.

Authors:  Camilla Praestegaard; Allan Jensen; Signe M Jensen; Thor S S Nielsen; Penelope M Webb; Christina M Nagle; Anna DeFazio; Estrid Høgdall; Mary Anne Rossing; Jennifer A Doherty; Kristine G Wicklund; Marc T Goodman; Francesmary Modugno; Kirsten Moysich; Roberta B Ness; Robert Edwards; Keitaro Matsuo; Satoyo Hosono; Ellen L Goode; Stacey J Winham; Brooke L Fridley; Daniel W Cramer; Kathryn L Terry; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Lisa E Paddock; Leon F Massuger; Nicolas Wentzensen; Paul Pharoah; Honglin Song; Alice Whittemore; Valerie McGuire; Weiva Sieh; Joseph Rothstein; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Alexandra Gentry-Maharaj; Anna H Wu; Celeste L Pearce; Malcolm Pike; Alice W Lee; Rebecca Sutphen; Jenny Chang-Claude; Harvey A Risch; Susanne K Kjaer
Journal:  Int J Cancer       Date:  2017-01-24       Impact factor: 7.396

5.  Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB.

Authors:  Feng Xiao; Ying Li; Weilai Xu; Liangshun You; Chunmei Yang; Hui Liu; Wenbin Qian
Journal:  Oncol Lett       Date:  2015-11-05       Impact factor: 2.967

6.  Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.

Authors:  Felicia T Roncolato; Florence Joly; Rachel O'Connell; Anne Lanceley; Felix Hilpert; Luke Buizen; Aikou Okamoto; Eriko Aotani; Sandro Pignata; Paul Donnellan; Amit Oza; Elisabeth Avall-Lundqvist; Jonathan S Berek; Florian Heitz; Amanda Feeney; Dominique Berton-Rigaud; Martin R Stockler; Madeleine King; Michael Friedlander
Journal:  Oncologist       Date:  2017-06-08

Review 7.  Brain metastasis from ovarian cancer: a systematic review.

Authors:  Shabnam Pakneshan; Damoun Safarpour; Fattaneh Tavassoli; Bahman Jabbari
Journal:  J Neurooncol       Date:  2014-05-01       Impact factor: 4.130

8.  Comparison of imputation methods for handling missing covariate data when fitting a Cox proportional hazards model: a resampling study.

Authors:  Andrea Marshall; Douglas G Altman; Roger L Holder
Journal:  BMC Med Res Methodol       Date:  2010-12-31       Impact factor: 4.615

9.  Modeling prognostic factors in resectable pancreatic adenocarcinomas.

Authors:  Taxiarchis Botsis; Valsamo K Anagnostou; Gunnar Hartvigsen; George Hripcsak; Chunhua Weng
Journal:  Cancer Inform       Date:  2010-01-20

10.  Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study.

Authors:  Andrea Marshall; Douglas G Altman; Patrick Royston; Roger L Holder
Journal:  BMC Med Res Methodol       Date:  2010-01-19       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.